Genprex, Inc. Files 8-K: Officer/Director Changes & Shareholder Votes
Ticker: GNPX · Form: 8-K · Filed: Aug 15, 2025 · CIK: 1595248
Sentiment: neutral
Topics: corporate-governance, officer-changes, shareholder-vote, financials
Related Tickers: GNPX
TL;DR
Genprex 8-K dropped: leadership shakeup, new officers, shareholder votes, and financials filed.
AI Summary
Genprex, Inc. filed an 8-K on August 15, 2025, reporting on several key events. These include the departure of directors or certain officers, the election of directors, the appointment of certain officers, and updates on compensatory arrangements for officers. The filing also covers the submission of matters to a vote of security holders and the presentation of financial statements and exhibits.
Why It Matters
This filing provides crucial updates on the company's leadership and governance, which can impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with shareholder votes, can indicate internal shifts or strategic decisions that may carry inherent risks.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- August 15, 2025 (date) — Date of report
FAQ
What specific officer or director positions were affected by departures or appointments?
The filing indicates changes in directors or certain officers and the appointment of certain officers, but does not specify the exact positions in this summary.
Were there any significant compensatory arrangements for officers disclosed?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of information, suggesting such arrangements are part of the report.
What matters were submitted to a vote of security holders?
The filing states 'Submission of Matters to a Vote of Security Holders' as an item, indicating such submissions occurred, but details are not provided in this summary.
Are the financial statements included in this filing preliminary or audited?
The filing lists 'Financial Statements and Exhibits' as an item, but the nature (preliminary or audited) is not specified in this summary.
What is Genprex, Inc.'s primary business sector?
Genprex, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' sector, with SIC code 2834.
Filing Stats: 1,324 words · 5 min read · ~4 pages · Grade level 12.6 · Accepted 2025-08-15 16:11:12
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20250708c_8k.htm (8-K) — 49KB
- ex_837023.htm (EX-10.1) — 144KB
- 0001437749-25-027138.txt ( ) — 353KB
- gnpx-20250815.xsd (EX-101.SCH) — 3KB
- gnpx-20250815_def.xml (EX-101.DEF) — 11KB
- gnpx-20250815_lab.xml (EX-101.LAB) — 15KB
- gnpx-20250815_pre.xml (EX-101.PRE) — 11KB
- gnpx20250708c_8k_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On August 15, 2025, Genprex held its 2025 Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the 2025 Annual Meeting, as set forth in the Company's Definitive Proxy Statement, filed with the Securities and Exchange Commission on July 16, 2025 (the "Proxy Statement"), were as follows: Proposal 1. Election of Director. The Class II director nominee, William R. Wilson, Jr., was elected to serve until the 2028 annual meeting of stockholders and until his respective successor has been duly elected and qualified, or until such director's earlier resignation, removal or death. The result of the vote to elect the Class II director was as follows: Name Votes For Votes Withheld Broker Non-Votes William R. Wilson, Jr. 5,626,859 545,921 9,600,549 Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The proposal to ratify the appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025 was approved by the stockholders based upon the following votes: Votes For Votes Against Abstention Broker Non-Votes 14,244,518 1,478,193 50,618 0 Proposal 3. Advisory Vote on Compensation of Named Executive Officers ( " NEOs " ). The votes were cast as follows with respect to the proposal to vote, on an advisory basis, on the compensation of the Company's NEOs as described in the Company's Proxy Statement: Votes For Votes Against Abstention Broker Non-Votes 4,089,289 1,791,592 291,899 9,600,549 Proposal 4. Approval of the Company' s Amended and Restated 2018 Equity Incentive Plan. The proposal to approve the Amended Equity Plan was approved by the stockholders based upon the following votes: Votes For Votes Against Abstention Broker Non-Votes 4,330,925 1,737,505 104,350 9,600,549 Proposal 5. Approval un
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Genprex, Inc. 2018 Equity Incentive Plan (As Amended and Restated Effective June 30, 2025). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: August 15, 2025 By: /s/ Ryan M. Confer Ryan M. Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)